CytoDyn Inc

(OTCQB:CYDY)

Latest On CytoDyn Inc (CYDY):

Date/Time Type Description Signal Details
2023-05-25 02:21 ESTNewsCytoDyn President Cyrus Arman takes medical leaveN/A
2023-03-28 17:00 ESTNewsCytoDyn: On The Cusp Of A New Beginning, Existing Shareholders BewareN/A
2022-12-30 03:52 ESTNewsCytoDyn: There Seems To Be No RedemptionN/A
2022-12-20 23:48 ESTNewsFormer CytoDyn CEO Pourhassan charged with defrauding investorsN/A
2022-10-29 01:48 ESTNewsCytoDyn voluntarily withdrawing BLA for HIV treatment leronlimabN/A
2022-10-17 10:28 ESTNewsCytoDyn: Repositioning And Refocusing With New LeadershipN/A
2022-08-25 07:12 ESTNewsCytoDyn: It Only Takes One HitN/A
2022-06-13 18:05 ESTNewsCytoDyn: Nearly Impossible To Revive This CompanyN/A
2022-03-31 05:13 ESTNewsCytoDyn: Holding Onto The Ruins From An End Of An EraN/A
2022-03-31 05:13 ESTNewsCytoDyn hit by clinical holds on HIV and COVID-19 programs in the U.S.N/A
2022-01-31 11:56 ESTNewsShort-term bounce for CytoDyn following CEO ousting not enough to stop slideN/A
2022-01-26 15:59 ESTNewsOusting of CytoDyn CEO Pourhassan boosts stock; shares up 12%N/A
2022-01-25 23:57 ESTNewsCytoDyn announces change in leadership to support approval and commercialization of leronlimabN/A
2022-01-07 15:15 ESTNewsCytoDyn: Moving Leronlimab Forward On All FrontsN/A
2022-01-05 15:25 ESTNewsCytoDyn's leronlimab in 350 mg weekly dose met endpoints in Phase 2 NASH trialN/A
2021-12-21 14:35 ESTNewsCytoDyn receives positive response from FDA for Phase 3 leronlimab study in COVID-19N/A
2021-12-18 11:19 ESTNewsCytoDyn Won't Make Your Dreams Come TrueN/A
2021-12-09 14:06 ESTNewsCytoDyn files for expanded access use of leronlimab for HIV patientsN/A
2021-11-24 11:58 ESTNewsCytoDyn reports leronlimab data in NASH trial for first 15 patientsN/A
2021-11-20 21:59 ESTNewsCytoDyn: Looking For A Turnaround Following Positive UpdatesN/A
2021-11-20 02:10 ESTNewsCytoDyn announces legal actions against its former CRO, Amarex Clinical ResearchN/A
2021-11-16 13:56 ESTNewsCytoDyn submits the first section of HIV BLA to FDA under rolling reviewN/A
2021-11-09 01:33 ESTNewsCytoDyn submits leronlimab Breakthrough Therapy designation application to the FDAN/A
2021-11-06 14:21 ESTNewsCytoDyn: Recent Data Warrants A Change In Game PlanN/A
2021-11-04 01:36 ESTNewsCytoDyn posts preliminary results from mid-stage leronlimab NASH studyN/A
2021-10-25 10:38 ESTNewsCytoDyn treats first patient in late-stage leronlimab Brazil COVID-19 trialN/A
2021-10-14 12:21 ESTNewsCytoDyn says Court ruled activist group’s nominations were InvalidN/A
2021-10-08 01:10 ESTNewsCytoDyn launches leronlimab study with immune checkpoint blockade for breast cancerN/A
2021-10-04 20:21 ESTNewsCytoDyn activists send Ziff/Bain Capital presentation critical of CEO to shareholdersN/A
2021-10-02 04:05 ESTNewsCytoDyn: Q4 Is Crunch TimeN/A
2021-09-30 06:43 ESTNewsCytodyn management calls activist group leronlimab plan 'misguided' and 'misleading'N/A
2021-09-24 20:04 ESTNewsCytoDyn shareholder group unveils plan to obtain cancer therapy approval for LeronlimabN/A
2021-09-22 17:37 ESTNewsCytoDyn gets greenlight for late-stage leronlimab COVID-19 trial in BrazilN/A
2021-09-10 14:20 ESTNewsEnrollment underway in CytoDyn's Phase 3 COVID-19 trial in BrazilN/A
2021-09-04 04:35 ESTNewsFederal judge finds CytoDyn shareholder group did not comply with SEC rulesN/A
2021-09-03 08:37 ESTNewsCytoDyn to hold webcast on September 8 to discuss HIV BLA status, COVID-19 trialsN/A
2021-09-02 12:43 ESTNewsCytoDyn shareholder group again outlines company failures, urges board changesN/A
2021-08-27 02:10 ESTNewsCytoDyn shareholder group sues company to allow alternative board nomineesN/A
2021-08-25 10:37 ESTNewsCytoDyn’s leronlimab increases overall and progression free survival in mTNBC patientsN/A
2021-08-18 02:49 ESTNewsCytoDyn: Biopharma's Troublemaker, Or Its Unappreciated GemN/A
2021-08-13 06:47 ESTNewsCytoDyn receives FDA guidance regarding BLA dose justification report for HIVN/A
2021-08-06 16:53 ESTNewsCytoDyn files lawsuit against activist group for 'misleading shareholders, illegal proxy contest'N/A
2021-08-04 00:46 ESTNewsCytoDyn gets Brazil regulatory clearance for late-stage COVID-19 trialN/A
2021-08-04 00:46 ESTNewsCytoDyn receives SEC, DOJ subpoenas related to leronlimab as a COVID-19 treatmentN/A
2021-08-03 05:30 ESTNewsCytoDyn claims that director nominees from activist group are invalid; shares drop 10%N/A
2021-07-22 16:09 ESTNewsCytoDyn's partner to submit request to conduct Phase 3 leronlimab studies in BrazilN/A
2021-07-22 16:09 ESTNewsCytoDyn gets first purchase order from Chiral Pharma for use of leronlimabN/A
2021-07-22 16:09 ESTNewsCytoDyn: Bulls And Bears Need To Come To Terms On COVID-19 EffortsN/A
2021-07-22 16:07 ESTNewsCytoDyn posts preliminary results from COVID-19 long-haulers studyN/A
2021-07-22 16:07 ESTNewsCytoDyn submits dose justification report to FDA for leronlimab BLA in HIVN/A

About CytoDyn Inc (CYDY):

CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). It has completed a Phase 3 pivotal trial with leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. The company is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. In addition, the company targets leronlimab treatment as a therapy for patients who experience respiratory complications as a result of contracting COVID-19, as well as Leronlimab for the prevention of graft-versus-host disease in patient. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

CYDY Quotes by TradingView

See Advanced Chart

General

  • Name CytoDyn Inc
  • Symbol CYDY
  • Type Common Stock
  • Exchange OTCQB
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 19
  • Fiscal Year EndMay
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.cytodyn.com
View More

Valuation

  • Forward PE 10.81
  • Price/Book (Most Recent Quarter) 1066.03
View More

Financials

  • Most Recent Quarter 2020-11-30
  • Current Year EPS Estimate -$0.21
  • Next Year EPS Estimate -$0.18
  • Return on Assets -77%
  • Earnings Per Share -$0.19
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.43 billion
  • EBITDA -53308416
  • Analyst Target Price $4
  • Book Value Per Share $0.01
View More

Share Statistics

  • Shares Outstanding 598.13 million
  • Shares Float 550.81 million
  • % Held by Insiders 853%
  • % Held by Institutions 0.11%
View More

Technicals

  • Beta -0.5
  • 52 Week High $10.01
  • 52 Week Low $0.91
  • 50 Day Moving Average 4.67
  • 200 Day Moving Average 3.87
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

CytoDyn Inc (CYDY) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

CytoDyn Inc (CYDY) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-11-302021-01-08$N/A-$0.06-$0.05-20%
2020-08-312020-10-09$N/A-$0.06-$0.060%
2020-05-312020-08-14$N/A-$0.13-$0.05-160%
2020-02-292020-04-09$N/A-$0.08-$0.03-166.67%
2019-11-302020-01-09$N/A-$0.04-$0.03-33.33%
2019-08-312019-10-08$N/A-$0.04-$0.040%
2019-05-312019-08-14$N/A-$0.05-$0.04-25%
2019-02-282019-04-09$N/A-$0.04-$0.0520%
2018-11-302019-01-09$N/A-$0.06-$0.05-20%
2018-08-312018-10-09$N/A-$0.07-$0.06-16.67%
2018-05-312018-07-27$N/A-$0.04-$0.0633.33%
2018-02-282018-04-09$N/A-$0.10-$0.07-42.86%
2017-11-302018-01-08$N/A-$0.07-$0.04-75%
2017-08-312017-10-10$N/A-$0.08-$0.05-60%
2017-05-312017-07-20$N/A-$0.05-$0.050%
2017-02-282017-04-13$N/A-$0.06-$0.04-50%
2016-11-302017-01-13$N/A-$0.04-$0.040%
2016-08-312016-10-12$N/A-$0.04-$0.0520%
2016-05-312016-07-19$N/A-$0.05-$0.04-25%
2016-02-292016-04-13$N/A-$0.05
2015-11-302016-01-11$N/A-$0.06
2015-08-312015-10-09$N/A-$0.12
2015-05-312015-07-10$N/A-$0.22
2015-02-282015-04-10$N/A-$0.05
2014-11-302015-01-12$N/A-$0.09
2014-08-312014-10-10$N/A-$0.06
2014-05-312014-05-31$N/A-$0.05
2014-02-282014-04-11$N/A-$0.06
2013-11-302014-01-13$N/A-$0.08
2013-08-312013-10-15$N/A-$0.08
2013-05-312013-08-29$N/A-$0.08
2013-02-282013-04-12$N/A-$0.08
2012-11-302013-01-14$N/A-$0.06
2012-08-312012-10-09$N/A-$0.10
2012-05-312012-08-22$N/A-$0.14
2012-02-292012-04-16$N/A-$0.06
2011-11-302012-01-17$N/A-$0.07
2011-08-312011-11-03$N/A-$0.05
2011-05-312011-05-31$N/A-$0.05
2011-02-282011-02-28$N/A-$0.05
2010-11-302010-11-30$N/A-$0.05
2010-08-312010-08-31$N/A-$0.03
2010-05-312010-05-31$N/A-$0.42
2010-02-282010-02-28$N/A-$0.04
2009-11-302009-11-30$N/A-$0.04
2009-08-312009-08-31$N/A-$0.02
2009-05-312009-05-31-$0.01
2009-02-282009-02-28-$0.02
2008-11-302008-11-30-$0.05
2008-08-312008-08-31-$0.04
2008-05-312008-05-31-$0.04
2008-02-292008-02-29-$0.02
2007-11-302007-11-30-$0.02
2007-08-312007-08-31-$0.02
2007-05-312007-05-31-$0.05
2007-02-282007-02-28-$0.05
2006-11-302006-11-30-$0.06
2006-08-312006-08-31-$0.08
2006-05-312006-05-31-$0.12
2006-02-282006-02-28-$0.03
2005-11-302005-11-30-$0.01

CytoDyn Inc (CYDY) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

CytoDyn Inc (CYDY) Chart:

CytoDyn Inc (CYDY) News:

Below you will find a list of latest news for CytoDyn Inc (CYDY) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

CytoDyn Inc (CYDY) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

CytoDyn Inc (CYDY) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000013/0001807094-20-000013-index.htm
2020-02-04UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1175680/000000000020001068/0000000000-20-001068-index.htm
2020-09-23UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1175680/000000000020008940/0000000000-20-008940-index.htm
2019-12-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000089924319030131/0000899243-19-030131-index.htm
2019-12-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000089924319030134/0000899243-19-030134-index.htm
2019-12-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000089924319030141/0000899243-19-030141-index.htm
2020-01-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000089924320000848/0000899243-20-000848-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000089924320000852/0000899243-20-000852-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000089924320000853/0000899243-20-000853-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000089924320000854/0000899243-20-000854-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000089924320005791/0000899243-20-005791-index.htm
2019-12-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1175680/000119312519325023/0001193125-19-325023-index.htm
2020-01-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1175680/000119312520004683/0001193125-20-004683-index.htm
2020-01-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520011073/0001193125-20-011073-index.htm
2020-01-31S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1175680/000119312520021372/0001193125-20-021372-index.htm
2020-02-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520022961/0001193125-20-022961-index.htm
2020-03-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520079100/0001193125-20-079100-index.htm
2020-03-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1175680/000119312520091124/0001193125-20-091124-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520099591/0001193125-20-099591-index.htm
2020-04-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1175680/000119312520102675/0001193125-20-102675-index.htm
2020-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520117325/0001193125-20-117325-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520121113/0001193125-20-121113-index.htm
2020-04-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520123383/0001193125-20-123383-index.htm
2020-04-30S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1175680/000119312520128998/0001193125-20-128998-index.htm
2020-05-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1175680/000119312520135276/0001193125-20-135276-index.htm
2020-06-028-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520157931/0001193125-20-157931-index.htm
2020-06-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520158615/0001193125-20-158615-index.htm
2020-06-08PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1175680/000119312520162421/0001193125-20-162421-index.htm
2020-06-08PRER14APreliminary Proxy Soliciting materialshttps://www.sec.gov/Archives/edgar/data/1175680/000119312520163711/0001193125-20-163711-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520174232/0001193125-20-174232-index.htm
2020-06-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1175680/000119312520174344/0001193125-20-174344-index.htm
2020-07-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520189699/0001193125-20-189699-index.htm
2020-07-08DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1175680/000119312520189750/0001193125-20-189750-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520198585/0001193125-20-198585-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520206701/0001193125-20-206701-index.htm
2020-08-1410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1175680/000119312520220598/0001193125-20-220598-index.htm
2020-08-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520223641/0001193125-20-223641-index.htm
2020-09-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1175680/000119312520237251/0001193125-20-237251-index.htm
2020-09-14424B7Prospectus [Rule 424(b)(7)]https://www.sec.gov/Archives/edgar/data/1175680/000119312520245212/0001193125-20-245212-index.htm
2020-09-15S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1175680/000119312520246304/0001193125-20-246304-index.htm
2020-09-23CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1175680/000119312520252346/0001193125-20-252346-index.htm
2020-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520259094/0001193125-20-259094-index.htm
2020-09-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1175680/000119312520259946/0001193125-20-259946-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1175680/000119312520261200/0001193125-20-261200-index.htm
2020-10-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1175680/000119312520266805/0001193125-20-266805-index.htm
2020-02-14DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000120919120009437/0001209191-20-009437-index.htm
2020-01-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000123489820000003/0001234898-20-000003-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000123489820000004/0001234898-20-000004-index.htm
2020-04-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000170244720000003/0001702447-20-000003-index.htm
2020-04-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000170244720000004/0001702447-20-000004-index.htm
2020-04-223/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000170244720000011/0001702447-20-000011-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000175424920000001/0001754249-20-000001-index.htm
2020-03-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000001/0001807094-20-000001-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000002/0001807094-20-000002-index.htm
2020-03-30DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000003/0001807094-20-000003-index.htm
2020-04-07D/ANotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000004/0001807094-20-000004-index.htm
2020-05-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2020-05-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/0001807094-20-000006-index.htm
2020-05-154/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/0001807094-20-000007-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000008/0001807094-20-000008-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000009/0001807094-20-000009-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000010/0001807094-20-000010-index.htm
2020-06-264/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000011/0001807094-20-000011-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000012/0001807094-20-000012-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000013/0001807094-20-000013-index.htm
2020-08-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000014/0001807094-20-000014-index.htm
2020-09-015Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000015/0001807094-20-000015-index.htm
2020-09-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000016/0001807094-20-000016-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000017/0001807094-20-000017-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000018/0001807094-20-000018-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000019/0001807094-20-000019-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000020/0001807094-20-000020-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000021/0001807094-20-000021-index.htm
2020-10-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000022/0001807094-20-000022-index.htm
2020-10-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000023/0001807094-20-000023-index.htm
2020-10-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000024/0001807094-20-000024-index.htm
2020-10-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000025/0001807094-20-000025-index.htm
2020-11-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1175680/000180709420000026/0001807094-20-000026-index.htm
2020-05-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1175680/999999999520001113/9999999995-20-001113-index.htm
2020-09-25EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1175680/999999999520002582/9999999995-20-002582-index.htm
2020-02-10SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1175680/999999999720000620/9999999997-20-000620-index.htm
2020-03-02SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1175680/999999999720001093/9999999997-20-001093-index.htm

CytoDyn Inc (CYDY) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of CytoDyn Inc (CYDY). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 853%
Institutional Ownership: 11%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-07-31Nader PourhassanPresident & CEOBuy323,157.001,231,500.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000014/0001807094-20-000014-index.htm
2020-05-01Scott A. KellyChief Medical OfficerBuy7,123.000.614,345.031,325,293.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/0001807094-20-000006-index.htm
2020-05-01Scott A. KellyChief Medical OfficerBuy75,000.000.5742,750.001,400,293.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/0001807094-20-000006-index.htm
2020-05-01Scott A. KellyChief Medical OfficerBuy97,009.000.5654,325.041,497,302.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/0001807094-20-000006-index.htm
2020-05-01Scott A. KellyChief Medical OfficerSell1,200,000.003.263,912,480.001,557,718.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/0001807094-20-000006-index.htm
2020-05-04Scott A. KellyChief Medical OfficerBuy8,334.000.524,333.681,566,052.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/0001807094-20-000006-index.htm
2020-09-30Nader PourhassanPresident & CEOBuy500,000.001,574,930.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000017/0001807094-20-000017-index.htm
2020-04-30Nader PourhassanPresident & CEOBuy600,000.001.09654,000.001,594,417.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2020-05-01Scott A. KellyChief Medical OfficerBuy100,000.000.4949,000.001,597,302.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/0001807094-20-000006-index.htm
2020-09-30Scott A. KellyChairman & CMOBuy250,000.001,741,052.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000018/0001807094-20-000018-index.htm
2020-04-30Nader PourhassanPresident & CEOBuy199,800.000.57113,886.001,794,217.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2020-05-01Scott A. KellyChief Medical OfficerBuy250,000.000.57141,250.001,847,302.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/0001807094-20-000006-index.htm
2020-05-01Scott A. KellyChief Medical OfficerBuy66,666.000.5234,666.321,913,968.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/0001807094-20-000006-index.htm
2020-10-16Mahboob U RahmanChief Scientific OfficerBuy200,000.00200,000.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000023/0001807094-20-000023-index.htm
2020-09-30Nitya G. RayChief Technology OfficerBuy200,000.00200,000.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000020/0001807094-20-000020-index.htm
2020-05-01Nader PourhassanPresident & CEOSell1,399,685.003.264,569,131.712,079,062.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2020-05-04Nader PourhassanPresident & CEOBuy30,933.000.3912,063.872,109,995.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2020-04-30Nader PourhassanPresident & CEOBuy600,000.000.80480,000.002,394,217.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2019-12-24Michael D. MulhollandSVP-FinanceBuy153,897.00241,023.00https://www.sec.gov/Archives/edgar/data/1175680/000089924319030131/0000899243-19-030131-index.htm
2020-04-30Nader PourhassanPresident & CEOBuy116,550.000.4957,109.502,510,767.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2020-05-01Scott A. KellyChief Medical OfficerBuy750,000.000.39288,750.002,663,968.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/0001807094-20-000006-index.htm
2020-05-01Scott A. KellyChief Medical OfficerBuy93,750.000.3936,562.502,757,718.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/0001807094-20-000006-index.htm
2020-09-30Michael D. MulhollandChief Financial OfficerBuy100,000.00284,081.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000019/0001807094-20-000019-index.htm
2020-04-30Nader PourhassanPresident & CEOSell2,219,837.003.537,838,688.413,478,747.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2020-04-30Nader PourhassanPresident & CEOBuy1,000,000.000.57565,000.003,510,767.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2020-04-30Nader PourhassanPresident & CEOBuy187,817.000.3973,248.633,698,584.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2019-12-24Nader PourhassanPresident & CEOBuy225,983.00387,472.00https://www.sec.gov/Archives/edgar/data/1175680/000089924319030134/0000899243-19-030134-index.htm
2020-04-30Nader PourhassanPresident & CEOBuy200,000.000.90180,000.00517,417.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2019-12-23David F WelchDirectorBuy1,639,344.005,252,676.00https://www.sec.gov/Archives/edgar/data/1175680/000089924319030141/0000899243-19-030141-index.htm
2020-04-30Nader PourhassanPresident & CEOBuy2,000,000.000.631,260,000.005,698,584.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2020-10-23Jordan G NaydenovDirectorBuy120,000.002.49298,308.006,257,823.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000024/0001807094-20-000024-index.htm
2020-11-02Jordan G NaydenovDirectorBuy193,500.002.57497,295.006,451,323.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000026/0001807094-20-000026-index.htm
2020-09-30Arian ColachisGC and Corporate SecretaryBuy70,000.0070,000.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000021/0001807094-20-000021-index.htm
2020-02-21David F WelchDirectorBuy1,819,672.000.18327,540.967,072,348.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000008/0001807094-20-000008-index.htm
2020-02-21David F WelchDirectorBuy181,967.007,254,315.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000008/0001807094-20-000008-index.htm
2020-10-23Arian ColachisGC and Corporate SecretaryBuy10,000.002.5025,000.0080,000.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000025/0001807094-20-000025-index.htm
2020-04-30Nader PourhassanPresident & CEOBuy325,000.000.87282,750.00842,417.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2020-05-04Nader PourhassanPresident & CEOSell1,201,652.002.793,353,089.74908,343.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm
2020-04-01David F WelchDirectorBuy2,259,102.000.501,129,551.009,513,417.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000008/0001807094-20-000008-index.htm
2020-04-30Nader PourhassanPresident & CEOBuy152,000.000.75114,000.00994,417.00https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/0001807094-20-000005-index.htm